Oral poly(ADP-ribose) polymerase-1 inhibitor BSI-401 has antitumor activity and synergizes with oxaliplatin against pancreatic cancer, preventing acute neurotoxicity

Clinical Cancer Research

Volumn 15, Issue 20, 2009, Pages 6367-6377

  Melisi, Davide ^a,c   Ossovskaya, Valeria ^b   Cihui, Zhu ^a   Rosa, Roberta ^a   Jianhua, Ling ^a   Dougherty, Patrick M ^a   Sherman, Barry M ^b   Abbruzzese, James L ^a   Chiao, Paul J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Bipar Sciences Inc   (United States)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BSI 401; GEMCITABINE; LUCIFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OXALIPLATIN; UNCLASSIFIED DRUG;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HUMAN; IN VITRO STUDY; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; NUDE MOUSE; PANCREAS CANCER; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; MICE; MICE, NUDE; NEUROTOXICITY SYNDROMES; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70350243066     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0910     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-2413 (Pubitemid 27251144)
3. Raymond E, Faivre S, Chaney S, Woynarowski J, CvitkovicE . Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 2002;1: 227-235
4. Damia G, D'Incalci M. Targeting DNA repair as a promising approach in cancer therapy. Eur J Cancer 2007;43:1791-1801 (Pubitemid 47238245)
5. Dantzer F, de La Rubia G, Menissier-De Murcia J, Hostomsky Z, de Murcia G, Schreiber V. Base excision repair is impaired in mammalian cells lacking Poly(ADP-ribose) polymerase-1. Biochemistry 2000;39:7559-7569 (Pubitemid 30422075)
6. Jagtap P, Szabo C. Poly(ADP-ribose) polymerase and the therapeuticeffec ts of its inhibitors. Nat Rev Drug Discov 2005;4:421-440 (Pubitemid 40704125)
7. Schreiber V, Dantzer F, Ame JC, de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 2006;7:517-528 (Pubitemid 44036457)
8. Plummer ER, Calvert H. Targeting poly(ADP-ribose) polymerase: a two-armed strategy for cancer therapy. Clin Cancer Res 2007;13:6252-6256 (Pubitemid 350075012)
9. Shiobara M, Miyazaki M, Ito H, et al. Enhanced polyadenosine diphosphate-ribosylation in cirrhoticli ver and carcinoma tissues in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2001;16:338-344 (Pubitemid 32374852)
10. de Murcia JM, Niedergang C, Trucco C, et al. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci U S A 1997;94:7303-7307 (Pubitemid 27345310)
11. Molinete M, Vermeulen W, Burkle A, et al. Overproduction of the poly(ADP-ribose) polymerase DNA-binding domain blocks alkylation-induced DNA repair synthesis in mammalian cells. EMBO J 1993;12:2109-2117 (Pubitemid 23157726)
12. Hans MA, Muller M, Meyer-Ficca M, Burkle A, Kupper JH. Overexpression of dominant negative PARP interferes with tumor formation of HeLa cells in nude mice: evidence for increased tumor cell apoptosis in vivo. Oncogene 1999;18: 7010-7015 (Pubitemid 30028871)
13. Ratnam K, Low JA. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res 2007;13: 1383-1388 (Pubitemid 46450426)
14. Pacher P, Liaudet L, Bai P, et al. Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. J Pharmacol Exp Ther 2002;300:862-867 (Pubitemid 34164989)
15. Szenczi O, Kemecsei P, Holthuijsen MF, et al. Poly(ADP-ribose) polymerase regulates myocardial calcium handling in doxorubicin-induced heart failure. Biochem Pharmacol 2005;69: 725-732 (Pubitemid 40248615)
16. Racz I, Tory K, Gallyas F, Jr., et al. BGP-15 - a novel poly(ADP-ribose) polymerase inhibitor- protects against nephrotoxicity of cisplatin without compromising its antitumor activity. Biochem Pharmacol 2002;63:1099-1111 (Pubitemid 34267025)
17. Kiernan MC, Krishnan AV. The pathophysiology of oxaliplatin-induced neurotoxicity. Curr Med Chem 2006;13:2901-2907
18. Szabo C, Virag L, Cuzzocrea S, et al. Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly (ADP-ribose) synthase. ProcNat l Acad Sci U S A 1998;95:3867-3872 (Pubitemid 28173220)
19. Scott GS, Szabo C, Hooper DC. Poly(ADP-ribose) polymerase activity contributes to peroxynitrite- induced spinal cord neuronal cell death in vitro. J Neurotrauma 2004;21:1255-1263 (Pubitemid 39280851)
20. Melisi D, Ishiyama S, Sclabas GM, et al. LY2109761, a novel transforming growth factor {β} receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther 2008;7: 829-840 (Pubitemid 351551036)
21. Wang ZQ, Auer B, Stingl L, et al. Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease. Genes Dev 1995;9:509-520
22. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
23. Matassov D, Kagan T, Leblanc J, Sikorska M, Zakeri Z. Measurement of apoptosis by DNA fragmentation. Methods Mol Biol 2004;282:1-17.
24. Plummer ER, Middleton MR, Jones C, et al. Temozolomide pharmacodynamics in patients with metastaticmelanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. Clin Cancer Res 2005;11:3402-3409 (Pubitemid 40627893)
25. Allchorne AJ, Broom DC, Woolf CJ. Detection of cold pain, cold allodynia and cold hyperalgesia in freely behaving rats. Mol Pain 2005;1:36.
26. Cata JP, Weng HR, Lee BN, Reuben JM, Dougherty PM. Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy. Minerva Anestesiol 2006;72:151-169
27. Choi Y, Yoon YW, Na HS, Kim SH, Chung JM. Behavioral signs of ongoing pain and cold allodynia in a rat model of neuropathicpain. Pain 1994;59:369-376
28. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434:913-917 (Pubitemid 40559005)
29. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeuticstrategy. Nature 2005;434:917-921 (Pubitemid 40559006)
30. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 2008;26:3785-3790
31. Fong PCBD, Carden CP, Roelvink M, et al. AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study. J Clin Oncol 2008;26. abstr 5510.
32. McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006; 66:8109-8115 (Pubitemid 44299177)
33. Chen Z, Xu XS, Harrison J, Wang G. Defining the function of xeroderma pigmentosum group F protein in psoralen interstrand cross-link-mediated DNA repair and mutagenesis. Biochem J 2004;379:71-78 (Pubitemid 38491361)
34. Linke SP, Sengupta S, Khabie N, et al. p53 interacts with hRAD51 and hRAD54, and directly modulates homologous recombination. Cancer Res 2003;63:2596-2605 (Pubitemid 36605201)
35. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-1966 (Pubitemid 46972777)
36. Cunningham DCI, Stocken D, Davies C, et al. Phase III randomised comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. Eur J Cancer Suppl 2005;3:12.
37. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005;23:3509-3516 (Pubitemid 46243495)
38. Poplin ELD, Berlin J, Rothenberg ML, et al. Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion[ FDR]) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer. J Clin Oncol 2006;24:LBA4004.
39. Calabrese CR, Almassy R, Barton S, et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 2004;96: 56-67. (Pubitemid 38180960)
40. Miknyoczki S, Chang H, Grobelny J, et al. The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity. Mol Cancer Ther 2007;6:2290-2302
41. Tentori L, Leonetti C, Scarsella M, et al. Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma. FASEB J 2006;20:1709-1711
42. Thomas HD, Calabrese CR, Batey MA, et al. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther 2007;6:945-956
43. Miknyoczki SJ, Jones-Bolin S, Pritchard S, et al. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly (ADP-ribose) polymerase inhibitor. Mol Cancer Ther 2003;2:371-382
44. Smith LM, Willmore E, Austin CA, Curtin NJ. The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks. Clin Cancer Res 2005; 11:8449-8457 (Pubitemid 41746960)
45. Evers B, Drost R, Schut E, et al. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res 2008;14:3916-3925
46. Donawho CK, Luo Y, Luo Y, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007;13:2728-2737 (Pubitemid 46795129)
47. Bowman KJ, White A, Golding BT, Griffin RJ, Curtin NJ. Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064. Br J Cancer 1998;78:1269-1277 (Pubitemid 28495236)
48. Adelsberger H, Quasthoff S, Grosskreutz J, Lepier A, Eckel F, Lersch C. The chemotherapeuticoxal iplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur J Pharmacol 2000;406:25-32. (Pubitemid 30697009)
49. Chiarugi A. Intrinsicmec hanisms of poly(ADP-ribose) neurotoxicity: three hypotheses. Neurotoxicology 2005;26:847-855 (Pubitemid 41427525)
50. Skaper SD. Poly(ADP-Ribose) polymerase-1 in acute neuronal death and inflammation: a strategy for neuroprotection. Ann N Y Acad Sci 2003; 993:217-28; discussion 87-88